 | • レポートコード：GIR-23F3912 • 出版社/出版日：GlobalInfoResearch / 2023年2月 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥501,120 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥751,680 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,002,240 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Recombinant Peptide Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界の組換えペプチドの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 組換えペプチド市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・グルカゴン、カルシトニン、その他 アプリケーション別セグメントは次のように区分されます。 ・腫瘍学、血液疾患、感染症、自己免疫疾患、その他 世界の組換えペプチド市場の主要なマーケットプレーヤーは以下のとおりです。 ・Sandoz Pharma、Stada Arzneimittel、Amgen、Hospira、Actavis、Cipla Ltd.、Wockhardt Ltd.、Biocon Ltd. 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - 組換えペプチドの概要 - タイプ別分析（2017年vs2021年vs2028年）：グルカゴン、カルシトニン、その他 - アプリケーション別分析（2017年vs2021年vs2028年）：腫瘍学、血液疾患、感染症、自己免疫疾患、その他 - 世界の組換えペプチド市場規模・予測 - 世界の組換えペプチド生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Sandoz Pharma、Stada Arzneimittel、Amgen、Hospira、Actavis、Cipla Ltd.、Wockhardt Ltd.、Biocon Ltd. ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：グルカゴン、カルシトニン、その他 ・アプリケーション別分析2017年-2028年：腫瘍学、血液疾患、感染症、自己免疫疾患、その他 ・組換えペプチドの北米市場分析 - 組換えペプチドの北米市場：タイプ別市場規模2017年-2028年 - 組換えペプチドの北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・組換えペプチドのヨーロッパ市場分析 - ：組換えペプチドのヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：組換えペプチドのヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・組換えペプチドのアジア太平洋市場分析 - 組換えペプチドのアジア太平洋市場：タイプ別市場規模2017年-2028年 - 組換えペプチドのアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・組換えペプチドの南米市場分析 - 組換えペプチドの南米市場：タイプ別市場規模2017年-2028年 - 組換えペプチドの南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・組換えペプチドの中東・アフリカ市場分析 - 組換えペプチドの中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 組換えペプチドの中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Recombinant Peptide market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Recombinant Peptide market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Oncology accounting for % of the Recombinant Peptide global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Glucagon segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Recombinant Peptide include Sandoz Pharma, Stada Arzneimittel, Amgen, Hospira, and Actavis, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Recombinant Peptide market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Glucagon
Calcitonin
Other
Market segment by Application can be divided into
Oncology
Blood Disorders
Infectious Diseases
Autoimmune Diseases
Other
The key market players for global Recombinant Peptide market are listed below:
Sandoz Pharma
Stada Arzneimittel
Amgen
Hospira
Actavis
Cipla Ltd.
Wockhardt Ltd.
Biocon Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Peptide product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Recombinant Peptide, with price, sales, revenue and global market share of Recombinant Peptide from 2019 to 2022.
Chapter 3, the Recombinant Peptide competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Peptide breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Recombinant Peptide market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Peptide.
Chapter 13, 14, and 15, to describe Recombinant Peptide sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Recombinant Peptide Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Recombinant Peptide Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Glucagon
1.2.3 Calcitonin
1.2.4 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Recombinant Peptide Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Oncology
1.3.3 Blood Disorders
1.3.4 Infectious Diseases
1.3.5 Autoimmune Diseases
1.3.6 Other
1.4 Global Recombinant Peptide Market Size & Forecast
1.4.1 Global Recombinant Peptide Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Recombinant Peptide Sales in Volume (2017-2028)
1.4.3 Global Recombinant Peptide Price (2017-2028)
1.5 Global Recombinant Peptide Production Capacity Analysis
1.5.1 Global Recombinant Peptide Total Production Capacity (2017-2028)
1.5.2 Global Recombinant Peptide Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Recombinant Peptide Market Drivers
1.6.2 Recombinant Peptide Market Restraints
1.6.3 Recombinant Peptide Trends Analysis
2 Manufacturers Profiles
2.1 Sandoz Pharma
2.1.1 Sandoz Pharma Details
2.1.2 Sandoz Pharma Major Business
2.1.3 Sandoz Pharma Recombinant Peptide Product and Services
2.1.4 Sandoz Pharma Recombinant Peptide Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Stada Arzneimittel
2.2.1 Stada Arzneimittel Details
2.2.2 Stada Arzneimittel Major Business
2.2.3 Stada Arzneimittel Recombinant Peptide Product and Services
2.2.4 Stada Arzneimittel Recombinant Peptide Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Amgen
2.3.1 Amgen Details
2.3.2 Amgen Major Business
2.3.3 Amgen Recombinant Peptide Product and Services
2.3.4 Amgen Recombinant Peptide Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Hospira
2.4.1 Hospira Details
2.4.2 Hospira Major Business
2.4.3 Hospira Recombinant Peptide Product and Services
2.4.4 Hospira Recombinant Peptide Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Actavis
2.5.1 Actavis Details
2.5.2 Actavis Major Business
2.5.3 Actavis Recombinant Peptide Product and Services
2.5.4 Actavis Recombinant Peptide Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Cipla Ltd.
2.6.1 Cipla Ltd. Details
2.6.2 Cipla Ltd. Major Business
2.6.3 Cipla Ltd. Recombinant Peptide Product and Services
2.6.4 Cipla Ltd. Recombinant Peptide Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Wockhardt Ltd.
2.7.1 Wockhardt Ltd. Details
2.7.2 Wockhardt Ltd. Major Business
2.7.3 Wockhardt Ltd. Recombinant Peptide Product and Services
2.7.4 Wockhardt Ltd. Recombinant Peptide Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Biocon Ltd.
2.8.1 Biocon Ltd. Details
2.8.2 Biocon Ltd. Major Business
2.8.3 Biocon Ltd. Recombinant Peptide Product and Services
2.8.4 Biocon Ltd. Recombinant Peptide Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Recombinant Peptide Breakdown Data by Manufacturer
3.1 Global Recombinant Peptide Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Recombinant Peptide Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Recombinant Peptide
3.4 Market Concentration Rate
3.4.1 Top 3 Recombinant Peptide Manufacturer Market Share in 2021
3.4.2 Top 6 Recombinant Peptide Manufacturer Market Share in 2021
3.5 Global Recombinant Peptide Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Recombinant Peptide Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Recombinant Peptide Market Size by Region
4.1.1 Global Recombinant Peptide Sales in Volume by Region (2017-2028)
4.1.2 Global Recombinant Peptide Revenue by Region (2017-2028)
4.2 North America Recombinant Peptide Revenue (2017-2028)
4.3 Europe Recombinant Peptide Revenue (2017-2028)
4.4 Asia-Pacific Recombinant Peptide Revenue (2017-2028)
4.5 South America Recombinant Peptide Revenue (2017-2028)
4.6 Middle East and Africa Recombinant Peptide Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Recombinant Peptide Sales in Volume by Type (2017-2028)
5.2 Global Recombinant Peptide Revenue by Type (2017-2028)
5.3 Global Recombinant Peptide Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Recombinant Peptide Sales in Volume by Application (2017-2028)
6.2 Global Recombinant Peptide Revenue by Application (2017-2028)
6.3 Global Recombinant Peptide Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Recombinant Peptide Sales by Type (2017-2028)
7.2 North America Recombinant Peptide Sales by Application (2017-2028)
7.3 North America Recombinant Peptide Market Size by Country
7.3.1 North America Recombinant Peptide Sales in Volume by Country (2017-2028)
7.3.2 North America Recombinant Peptide Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Recombinant Peptide Sales by Type (2017-2028)
8.2 Europe Recombinant Peptide Sales by Application (2017-2028)
8.3 Europe Recombinant Peptide Market Size by Country
8.3.1 Europe Recombinant Peptide Sales in Volume by Country (2017-2028)
8.3.2 Europe Recombinant Peptide Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Recombinant Peptide Sales by Type (2017-2028)
9.2 Asia-Pacific Recombinant Peptide Sales by Application (2017-2028)
9.3 Asia-Pacific Recombinant Peptide Market Size by Region
9.3.1 Asia-Pacific Recombinant Peptide Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Recombinant Peptide Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Recombinant Peptide Sales by Type (2017-2028)
10.2 South America Recombinant Peptide Sales by Application (2017-2028)
10.3 South America Recombinant Peptide Market Size by Country
10.3.1 South America Recombinant Peptide Sales in Volume by Country (2017-2028)
10.3.2 South America Recombinant Peptide Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Recombinant Peptide Sales by Type (2017-2028)
11.2 Middle East & Africa Recombinant Peptide Sales by Application (2017-2028)
11.3 Middle East & Africa Recombinant Peptide Market Size by Country
11.3.1 Middle East & Africa Recombinant Peptide Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Recombinant Peptide Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Recombinant Peptide and Key Manufacturers
12.2 Manufacturing Costs Percentage of Recombinant Peptide
12.3 Recombinant Peptide Production Process
12.4 Recombinant Peptide Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Recombinant Peptide Typical Distributors
13.3 Recombinant Peptide Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Recombinant Peptide Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Recombinant Peptide Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Sandoz Pharma Basic Information, Manufacturing Base and Competitors
Table 4. Sandoz Pharma Major Business
Table 5. Sandoz Pharma Recombinant Peptide Product and Services
Table 6. Sandoz Pharma Recombinant Peptide Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Stada Arzneimittel Basic Information, Manufacturing Base and Competitors
Table 8. Stada Arzneimittel Major Business
Table 9. Stada Arzneimittel Recombinant Peptide Product and Services
Table 10. Stada Arzneimittel Recombinant Peptide Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Amgen Basic Information, Manufacturing Base and Competitors
Table 12. Amgen Major Business
Table 13. Amgen Recombinant Peptide Product and Services
Table 14. Amgen Recombinant Peptide Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Hospira Basic Information, Manufacturing Base and Competitors
Table 16. Hospira Major Business
Table 17. Hospira Recombinant Peptide Product and Services
Table 18. Hospira Recombinant Peptide Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Actavis Basic Information, Manufacturing Base and Competitors
Table 20. Actavis Major Business
Table 21. Actavis Recombinant Peptide Product and Services
Table 22. Actavis Recombinant Peptide Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Cipla Ltd. Basic Information, Manufacturing Base and Competitors
Table 24. Cipla Ltd. Major Business
Table 25. Cipla Ltd. Recombinant Peptide Product and Services
Table 26. Cipla Ltd. Recombinant Peptide Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Wockhardt Ltd. Basic Information, Manufacturing Base and Competitors
Table 28. Wockhardt Ltd. Major Business
Table 29. Wockhardt Ltd. Recombinant Peptide Product and Services
Table 30. Wockhardt Ltd. Recombinant Peptide Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Biocon Ltd. Basic Information, Manufacturing Base and Competitors
Table 32. Biocon Ltd. Major Business
Table 33. Biocon Ltd. Recombinant Peptide Product and Services
Table 34. Biocon Ltd. Recombinant Peptide Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Global Recombinant Peptide Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 36. Global Recombinant Peptide Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 37. Market Position of Manufacturers in Recombinant Peptide, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 38. Global Recombinant Peptide Production Capacity by Company, (K Units): 2020 VS 2021
Table 39. Head Office and Recombinant Peptide Production Site of Key Manufacturer
Table 40. Recombinant Peptide New Entrant and Capacity Expansion Plans
Table 41. Recombinant Peptide Mergers & Acquisitions in the Past Five Years
Table 42. Global Recombinant Peptide Sales by Region (2017-2022) & (K Units)
Table 43. Global Recombinant Peptide Sales by Region (2023-2028) & (K Units)
Table 44. Global Recombinant Peptide Revenue by Region (2017-2022) & (USD Million)
Table 45. Global Recombinant Peptide Revenue by Region (2023-2028) & (USD Million)
Table 46. Global Recombinant Peptide Sales by Type (2017-2022) & (K Units)
Table 47. Global Recombinant Peptide Sales by Type (2023-2028) & (K Units)
Table 48. Global Recombinant Peptide Revenue by Type (2017-2022) & (USD Million)
Table 49. Global Recombinant Peptide Revenue by Type (2023-2028) & (USD Million)
Table 50. Global Recombinant Peptide Price by Type (2017-2022) & (US$/Unit)
Table 51. Global Recombinant Peptide Price by Type (2023-2028) & (US$/Unit)
Table 52. Global Recombinant Peptide Sales by Application (2017-2022) & (K Units)
Table 53. Global Recombinant Peptide Sales by Application (2023-2028) & (K Units)
Table 54. Global Recombinant Peptide Revenue by Application (2017-2022) & (USD Million)
Table 55. Global Recombinant Peptide Revenue by Application (2023-2028) & (USD Million)
Table 56. Global Recombinant Peptide Price by Application (2017-2022) & (US$/Unit)
Table 57. Global Recombinant Peptide Price by Application (2023-2028) & (US$/Unit)
Table 58. North America Recombinant Peptide Sales by Country (2017-2022) & (K Units)
Table 59. North America Recombinant Peptide Sales by Country (2023-2028) & (K Units)
Table 60. North America Recombinant Peptide Revenue by Country (2017-2022) & (USD Million)
Table 61. North America Recombinant Peptide Revenue by Country (2023-2028) & (USD Million)
Table 62. North America Recombinant Peptide Sales by Type (2017-2022) & (K Units)
Table 63. North America Recombinant Peptide Sales by Type (2023-2028) & (K Units)
Table 64. North America Recombinant Peptide Sales by Application (2017-2022) & (K Units)
Table 65. North America Recombinant Peptide Sales by Application (2023-2028) & (K Units)
Table 66. Europe Recombinant Peptide Sales by Country (2017-2022) & (K Units)
Table 67. Europe Recombinant Peptide Sales by Country (2023-2028) & (K Units)
Table 68. Europe Recombinant Peptide Revenue by Country (2017-2022) & (USD Million)
Table 69. Europe Recombinant Peptide Revenue by Country (2023-2028) & (USD Million)
Table 70. Europe Recombinant Peptide Sales by Type (2017-2022) & (K Units)
Table 71. Europe Recombinant Peptide Sales by Type (2023-2028) & (K Units)
Table 72. Europe Recombinant Peptide Sales by Application (2017-2022) & (K Units)
Table 73. Europe Recombinant Peptide Sales by Application (2023-2028) & (K Units)
Table 74. Asia-Pacific Recombinant Peptide Sales by Region (2017-2022) & (K Units)
Table 75. Asia-Pacific Recombinant Peptide Sales by Region (2023-2028) & (K Units)
Table 76. Asia-Pacific Recombinant Peptide Revenue by Region (2017-2022) & (USD Million)
Table 77. Asia-Pacific Recombinant Peptide Revenue by Region (2023-2028) & (USD Million)
Table 78. Asia-Pacific Recombinant Peptide Sales by Type (2017-2022) & (K Units)
Table 79. Asia-Pacific Recombinant Peptide Sales by Type (2023-2028) & (K Units)
Table 80. Asia-Pacific Recombinant Peptide Sales by Application (2017-2022) & (K Units)
Table 81. Asia-Pacific Recombinant Peptide Sales by Application (2023-2028) & (K Units)
Table 82. South America Recombinant Peptide Sales by Country (2017-2022) & (K Units)
Table 83. South America Recombinant Peptide Sales by Country (2023-2028) & (K Units)
Table 84. South America Recombinant Peptide Revenue by Country (2017-2022) & (USD Million)
Table 85. South America Recombinant Peptide Revenue by Country (2023-2028) & (USD Million)
Table 86. South America Recombinant Peptide Sales by Type (2017-2022) & (K Units)
Table 87. South America Recombinant Peptide Sales by Type (2023-2028) & (K Units)
Table 88. South America Recombinant Peptide Sales by Application (2017-2022) & (K Units)
Table 89. South America Recombinant Peptide Sales by Application (2023-2028) & (K Units)
Table 90. Middle East & Africa Recombinant Peptide Sales by Region (2017-2022) & (K Units)
Table 91. Middle East & Africa Recombinant Peptide Sales by Region (2023-2028) & (K Units)
Table 92. Middle East & Africa Recombinant Peptide Revenue by Region (2017-2022) & (USD Million)
Table 93. Middle East & Africa Recombinant Peptide Revenue by Region (2023-2028) & (USD Million)
Table 94. Middle East & Africa Recombinant Peptide Sales by Type (2017-2022) & (K Units)
Table 95. Middle East & Africa Recombinant Peptide Sales by Type (2023-2028) & (K Units)
Table 96. Middle East & Africa Recombinant Peptide Sales by Application (2017-2022) & (K Units)
Table 97. Middle East & Africa Recombinant Peptide Sales by Application (2023-2028) & (K Units)
Table 98. Recombinant Peptide Raw Material
Table 99. Key Manufacturers of Recombinant Peptide Raw Materials
Table 100. Direct Channel Pros & Cons
Table 101. Indirect Channel Pros & Cons
Table 102. Recombinant Peptide Typical Distributors
Table 103. Recombinant Peptide Typical Customers
List of Figures
Figure 1. Recombinant Peptide Picture
Figure 2. Global Recombinant Peptide Revenue Market Share by Type in 2021
Figure 3. Glucagon
Figure 4. Calcitonin
Figure 5. Other
Figure 6. Global Recombinant Peptide Revenue Market Share by Application in 2021
Figure 7. Oncology
Figure 8. Blood Disorders
Figure 9. Infectious Diseases
Figure 10. Autoimmune Diseases
Figure 11. Other
Figure 12. Global Recombinant Peptide Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 13. Global Recombinant Peptide Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Recombinant Peptide Sales (2017-2028) & (K Units)
Figure 15. Global Recombinant Peptide Price (2017-2028) & (US$/Unit)
Figure 16. Global Recombinant Peptide Production Capacity (2017-2028) & (K Units)
Figure 17. Global Recombinant Peptide Production Capacity by Geographic Region: 2022 VS 2028
Figure 18. Recombinant Peptide Market Drivers
Figure 19. Recombinant Peptide Market Restraints
Figure 20. Recombinant Peptide Market Trends
Figure 21. Global Recombinant Peptide Sales Market Share by Manufacturer in 2021
Figure 22. Global Recombinant Peptide Revenue Market Share by Manufacturer in 2021
Figure 23. Recombinant Peptide Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 24. Top 3 Recombinant Peptide Manufacturer (Revenue) Market Share in 2021
Figure 25. Top 6 Recombinant Peptide Manufacturer (Revenue) Market Share in 2021
Figure 26. Global Recombinant Peptide Sales Market Share by Region (2017-2028)
Figure 27. Global Recombinant Peptide Revenue Market Share by Region (2017-2028)
Figure 28. North America Recombinant Peptide Revenue (2017-2028) & (USD Million)
Figure 29. Europe Recombinant Peptide Revenue (2017-2028) & (USD Million)
Figure 30. Asia-Pacific Recombinant Peptide Revenue (2017-2028) & (USD Million)
Figure 31. South America Recombinant Peptide Revenue (2017-2028) & (USD Million)
Figure 32. Middle East & Africa Recombinant Peptide Revenue (2017-2028) & (USD Million)
Figure 33. Global Recombinant Peptide Sales Market Share by Type (2017-2028)
Figure 34. Global Recombinant Peptide Revenue Market Share by Type (2017-2028)
Figure 35. Global Recombinant Peptide Price by Type (2017-2028) & (US$/Unit)
Figure 36. Global Recombinant Peptide Sales Market Share by Application (2017-2028)
Figure 37. Global Recombinant Peptide Revenue Market Share by Application (2017-2028)
Figure 38. Global Recombinant Peptide Price by Application (2017-2028) & (US$/Unit)
Figure 39. North America Recombinant Peptide Sales Market Share by Type (2017-2028)
Figure 40. North America Recombinant Peptide Sales Market Share by Application (2017-2028)
Figure 41. North America Recombinant Peptide Sales Market Share by Country (2017-2028)
Figure 42. North America Recombinant Peptide Revenue Market Share by Country (2017-2028)
Figure 43. United States Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Canada Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Mexico Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Europe Recombinant Peptide Sales Market Share by Type (2017-2028)
Figure 47. Europe Recombinant Peptide Sales Market Share by Application (2017-2028)
Figure 48. Europe Recombinant Peptide Sales Market Share by Country (2017-2028)
Figure 49. Europe Recombinant Peptide Revenue Market Share by Country (2017-2028)
Figure 50. Germany Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific Recombinant Peptide Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Recombinant Peptide Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific Recombinant Peptide Sales Market Share by Region (2017-2028)
Figure 58. Asia-Pacific Recombinant Peptide Revenue Market Share by Region (2017-2028)
Figure 59. China Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Korea Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Recombinant Peptide Sales Market Share by Type (2017-2028)
Figure 66. South America Recombinant Peptide Sales Market Share by Application (2017-2028)
Figure 67. South America Recombinant Peptide Sales Market Share by Country (2017-2028)
Figure 68. South America Recombinant Peptide Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East & Africa Recombinant Peptide Sales Market Share by Type (2017-2028)
Figure 72. Middle East & Africa Recombinant Peptide Sales Market Share by Application (2017-2028)
Figure 73. Middle East & Africa Recombinant Peptide Sales Market Share by Region (2017-2028)
Figure 74. Middle East & Africa Recombinant Peptide Revenue Market Share by Region (2017-2028)
Figure 75. Turkey Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Egypt Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Saudi Arabia Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. South Africa Recombinant Peptide Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Manufacturing Cost Structure Analysis of Recombinant Peptide in 2021
Figure 80. Manufacturing Process Analysis of Recombinant Peptide
Figure 81. Recombinant Peptide Industrial Chain
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
Figure 83. Methodology
Figure 84. Research Process and Data Source
• 日本語訳：組換えペプチドのグローバル市場2022年
• レポートコード：GIR-23F3912 ▷ お問い合わせ（見積依頼・ご注文・質問）